Sign In
Buy APLM
$20.09
-2.74 (-12.00%)
At Close: Jun 23, 2026
Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer
08:30am, Thursday, 16'th Nov 2023
Apollomics' partner, Avistone Biotechnology, received approval from Chinese National Medical Products Administration (NMPA) to commercialize vebreltinib (APL-101) in China Compelling clinical data ser
FOSTER CITY, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult
Why Is Apollomics (APLM) Stock Up 113% Today?
08:03am, Friday, 27'th Oct 2023
Apollomics (NASDAQ: APLM ) stock is rising higher on Friday as the shares bounce back on recent study results. Those study results cover the “efficacy response of a patient treated with vebreltinib
Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion
08:50am, Thursday, 26'th Oct 2023
FOSTER CITY, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the “Company”), today announced a report by the Veneto Institute of Oncology on the efficacy response of a pa
FOSTER CITY, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the “Company”), today announced the presentation of vebreltinib efficacy and safety data from the KUNPENG cli
Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023
06:55pm, Monday, 16'th Oct 2023
FOSTER CITY, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates
Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update
04:17pm, Thursday, 28'th Sep 2023
Phase 2 data from vebreltinib (APL-101), a highly selective cMet inhibitor, in patients with NSCLC with MET exon14 skipping mutation expected second half 2023
Apollomics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
07:00am, Wednesday, 06'th Sep 2023
FOSTER CITY, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates
Apollomics: A Taiwanese-Origin Company With Late Stage Pipeline
06:21am, Tuesday, 29'th Aug 2023
Apollomics is a small company with a pipeline of c-Met targeting small molecule TKIs for various cancers. Their lead candidate, Vebreltinib, is in phase 2 trials for NSCLC, GBM, and other solid tumors
The 7 Most Promising Penny Stocks to Buy in June
08:56pm, Wednesday, 07'th Jun 2023
Some of the most promising penny stocks are up-and-coming and just just getting started. The world of penny stocks is all about speculating which young firms have the potential to become the next big
Why Shares of Apollomics Are Up Friday
11:20am, Friday, 02'nd Jun 2023
Apollomics focuses on therapies for hard-to-treat cancers. The company has nine therapies, with six in clinical trials.
Top 5 Health Care Stocks That Are Preparing To Pump In Q2 - AngioDynamics (NASDAQ:ANGO), Apollomics (NASDAQ:APLM)
07:45am, Wednesday, 26'th Apr 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
